Characterization of Streptococcus pneumoniae detected in clinical respiratory tract samples in southern Sweden 2 to 4 years after introduction of PCV13 - 24/07/21
Highlights |
• | Serotype 19A but not 3 declines in mucosal infections after introduction of PCV13. |
• | Serotype 19A remains present and may reemerge in pediatric IPD if PCV13 is halted. |
• | Respiratory and invasive infections are caused by different nonvaccine serotypes. |
• | Certain replacement serotypes are associated with important antimicrobial resistance. |
Summary |
Objective |
To determine the serotype distribution and antimicrobial resistance of Streptococcus pneumoniae associated with mucosal infections in patients of all ages, 2 to 4 years after the transition from a 10-valent pneumococcal conjugate vaccine (PCV10) to PCV13 in the childhood immunization programme.
Methods |
Background information and antimicrobial susceptibility data regarding all respiratory tract, middle ear, and conjunctival samples positive for growth of S. pneumoniae (n = 2,131) were collected during 18 months in 2016–2018. Available corresponding bacterial isolates were serotyped by PCR and/or antisera (n = 1,858).
Results |
In total, 17% of isolates were covered by PCV13, predominantly represented by serotypes 3 (9%) and 19A (5%). The most common nonvaccine serotypes were 11A (10%), 23B (10%), 15A (6%) and 35F (5%). Isolates exhibiting serotype 15A or 23B were often multidrug-resistant (21%) or penicillin nonsusceptible (38%), respectively.
Conclusions |
The overall proportion of serotype 19A was halved compared to a previous observation period when PCV10 was used (years 2011–2013), suggesting herd protection related to PCV13. The proportion of serotype 3 was, however, unchanged. Despite most nonvaccine serotypes causing mucosal infections have a low invasive potential, certain antibiotic resistant serotypes may pose a clinical problem.
Le texte complet de cet article est disponible en PDF.Keywords : Antimicrobial resistance, Epidemiology, Respiratory tract infection, Serotype, Streptococcus pneumoniae
Plan
Vol 83 - N° 2
P. 190-196 - août 2021 Retour au numéro
Article précédent
- Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers
- Richard J. Everts, Sharon J. Gardiner, Mei Zhang, Ronald Begg, Stephen T. Chambers, John Turnidge, Evan J. Begg
- Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks
- Jacques Fantini, Nouara Yahi, Fodil Azzaz, Henri Chahinian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?